Prestige Biologics signs ₩15.5bn commercial API manufacturing supply contract
Prestige Biologics Co., Ltd. filed a supply contract dated Nov 12, 2026 for commercial active pharmaceutical ingredient contract manufacturing, with a contract amount of ₩15.5bn. The filing reports the contract as 58.1% of revenue. The contract period runs from Nov 12, 2026 to Dec 31, 2027.
Key facts
| Contract name | Commercial active pharmaceutical ingredient (API) contract manufacturing agreement |
|---|---|
| Contract amount | ₩15.5bn |
| % of revenue (as reported) | 58.1% |
| Period start | Nov 12, 2026 |
| Period end | Dec 31, 2027 |
Comparison
| Amount as % of prior-year revenue (calculated) | 123.6% |
|---|---|
| Revenue 2025 | ₩12.5bn |
| Revenue 2024 | ₩2.2bn |
| Revenue 2023 | ₩1.7bn |
Context
The contract amount is reported as 58.1% of the company's revenue. By our calculation, the ₩15.5bn amount is 123.6% of FY2025 revenue of ₩12.5bn. The filing does not describe any change to the share count or any share issuance.
Key metrics
Supply contracts
| Supply contracts, last 12 months | ₩39.2bn |
|---|---|
| Supply contracts vs prior-year revenue | 312.7% |
| Contracts without a KRW amount | 0 contracts without a KRW amount excluded |
Source: DART (Financial Supervisory Service) · Original filing on DART ↗